Business Wire

BEARINGPOINT

3.3.2020 09:02:13 CET | Business Wire | Press release

Share
BearingPoint posts strong 2019 as it starts executing its Strategy 2025

Management and technology consultancy BearingPoint announced today that full-year 2019 revenues hit a record €780 million, a 6% increase from the previous year, due in particular to new revenue streams and innovative business services. The firm delivered projects for clients in over 70 countries. Bookings for 2019 came in at €949 million, which was up 15% compared to the prior year. The substantial growth in bookings points to a strong 2020. BearingPoint said its Strategy 2025, launched last year, has created a solid foundation for sustainable growth. To support growth, BearingPoint hired 1,400 people last year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005041/en/

“In 2019, we laid the foundation for the future of our firm by developing our Strategy 2025. Three major ambitions drive this strategy. One, we put people in the center. Two, we’re going to outperform the market every year. Three, we’re going to be within the top three players in selected areas we decide to play,” said Managing Partner Kiumars Hamidian. “Despite difficult market conditions in certain segments and market geographies, our firm proved to be resilient and able to grow. 2020 is all about the execution of our strategy. Our backlog is strong, the market conditions in most of our countries are promising, and team spirit is extremely high.”

Strategic growth and innovation

BearingPoint established Business Services as a separate unit at the beginning of 2019. Business Services provides IP-driven digital assets and managed services beyond SaaS. The firm also accelerated the growth of its software business by further verticalizing its two product lines: BearingPoint Beyond and BearingPoint RegTech. BearingPoint Beyond is a digital platform solution provider that helps organizations reinvent their business model and grow revenue by utilizing digital platforms and partner ecosystems. BearingPoint RegTech is a leading provider of innovative regulatory and risk technology solutions and launched an international “regulatory reporting factory” last year.

To support its overall growth objectives, BearingPoint also made a strategic move by acquiring Prederi, a leading consultancy focused on public services in the UK. With the acquisition, BearingPoint continued its growth strategy in selected markets with consultancies that are highly focused and strongly differentiated.

Once again, there was a strong focus on creating innovation. More than 130 ideas, startups, and initiatives were submitted to the firm’s “Hub of Innovation,” and over 20 minimum viable products (MVPs) were developed. Market observers again singled out BearingPoint in 2019 for its innovation and strengths, with 90 analyst recognitions and various awards.

Putting people in the center

As part of putting people at the center, one of the three core ambitions of its Strategy 2025, BearingPoint established a long-term incentive plan that rewards employee loyalty. The firm also established LGBTQ+ and All Inclusive communities and expanded its (Y)Our Ways program. BearingPoint’s (Y)Our Ways is about redesigning the way people work to achieve tangible business outcomes. It leverages IP, talent, and expertise. People-centric by design, (Y)Our Ways is transforming the way BearingPoint makes a difference for its people, clients, and ecosystems.

10 years of BearingPoint – 10 years of success

In 2019, BearingPoint celebrated 10 years of success as an independent, Partner-led management and technology consultancy by giving back to people, planet, and society in the biggest CSR campaign in the firm’s history. The #10DaysOfCaring campaign saw BearingPoint’s people across its offices worldwide participate in more than 150 different activities ranging from planting trees and cycling to work to donating blood and volunteering for local nonprofits. BearingPoint said that #10DaysOfCaring underlined the firm’s culture of teamwork, creativity, and a can-do attitude.

BearingPoint used the momentum from the campaign to start new initiatives, like launching new affinity networks. The firm also signed the UN Global Compact in 2019 and committed itself to the 10 underlying principles that include environmental and climate protection. One way BearingPoint showed its commitment was by making its business travel activities climate-neutral for all its business units globally.

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.

BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye